2 x 125 µg of HeLa whole-cell extract at 2.5 µg/µl.
HeLa whole-cell extract was prepared from a cell culture of the HeLa human epithelial carcinoma cell line. The HeLa cell line was originally derived from cells obtained in 1951 from Henrietta Lacks, a cervical cancer patient who eventually died from her cancer. The HeLa cell line is one of the oldest and most commonly utilized immortal cell lines in scientific research. These cells are highly prolific and easily sustainable, allowing for flexibility in their application in various fields of scientific research, including cancer biology, virology, and human disease. To date, over 60,000 publications across various disciplines have referenced the use of HeLa cells.
HeLa whole cell extract is recommended for use in various applications across many research areas, including cancer, virology, and gene mapping studies.
Human Cervix Adenocarcinoma
HeLa whole-cell extract was collected in Lysis Buffer after a 30-minute mock stimulation. Lysis Buffer consists of 20 mM Hepes pH 7.5, 350 mM NaCl, 20% glycerol, 1% Igepal-CA630, 1 mM MgCl2, 0.5 mM EDTA and 0.1 mM EGTA. The protein content has been determined by a Bradford-based assay.
Each lot has been tested for NFκB activation by using TransAM® NFκB Kits. The signal intensity for NFκB activation in each lot is compared to the signal intensity obtained with extracts from unstimulated HeLa cells (see figure). After the signals are blanked, the ratio of the signals from stimulated cells over unstimulated cells must be above 4. This ratio may vary depending on the basal level of NFκB activation in a given cell type.
To ensure stability, extracts should be stored at -80°C.
We recommend aliquoting the extracts into single-use fractions and then storing them at -80°C. This eliminates repeated freeze/thaw cycles.
This product is guaranteed for 6 months from date of receipt.
This product is for research use only and is not for use in diagnostic procedures.